Literature DB >> 15263907

Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence.

P J Harrison1, D R Weinberger.   

Abstract

This review critically summarizes the neuropathology and genetics of schizophrenia, the relationship between them, and speculates on their functional convergence. The morphological correlates of schizophrenia are subtle, and range from a slight reduction in brain size to localized alterations in the morphology and molecular composition of specific neuronal, synaptic, and glial populations in the hippocampus, dorsolateral prefrontal cortex, and dorsal thalamus. These findings have fostered the view of schizophrenia as a disorder of connectivity and of the synapse. Although attractive, such concepts are vague, and differentiating primary events from epiphenomena has been difficult. A way forward is provided by the recent identification of several putative susceptibility genes (including neuregulin, dysbindin, COMT, DISC1, RGS4, GRM3, and G72). We discuss the evidence for these and other genes, along with what is known of their expression profiles and biological roles in brain and how these may be altered in schizophrenia. The evidence for several of the genes is now strong. However, for none, with the likely exception of COMT, has a causative allele or the mechanism by which it predisposes to schizophrenia been identified. Nevertheless, we speculate that the genes may all converge functionally upon schizophrenia risk via an influence upon synaptic plasticity and the development and stabilization of cortical microcircuitry. NMDA receptor-mediated glutamate transmission may be especially implicated, though there are also direct and indirect links to dopamine and GABA signalling. Hence, there is a correspondence between the putative roles of the genes at the molecular and synaptic levels and the existing understanding of the disorder at the neural systems level. Characterization of a core molecular pathway and a 'genetic cytoarchitecture' would be a profound advance in understanding schizophrenia, and may have equally significant therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15263907     DOI: 10.1038/sj.mp.4001558

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  672 in total

1.  Severe cross-modal object recognition deficits in rats treated sub-chronically with NMDA receptor antagonists are reversed by systemic nicotine: implications for abnormal multisensory integration in schizophrenia.

Authors:  Derek L Jacklin; Amit Goel; Kyle J Clementino; Alexander W M Hall; John C Talpos; Boyer D Winters
Journal:  Neuropsychopharmacology       Date:  2012-06-06       Impact factor: 7.853

2.  Disrupted activity in the hippocampal-accumbens circuit of type III neuregulin 1 mutant mice.

Authors:  Malcolm W Nason; Avishek Adhikari; Marjan Bozinoski; Joshua A Gordon; Lorna W Role
Journal:  Neuropsychopharmacology       Date:  2010-10-06       Impact factor: 7.853

3.  Nucleocytoplasmic shuttling of dysbindin-1, a schizophrenia-related protein, regulates synapsin I expression.

Authors:  Erkang Fei; Xiaochuan Ma; Cuiqing Zhu; Ting Xue; Jie Yan; Yuxia Xu; Jiangning Zhou; Guanghui Wang
Journal:  J Biol Chem       Date:  2010-10-04       Impact factor: 5.157

4.  Association of PDE4B polymorphisms and schizophrenia in Northwestern Han Chinese.

Authors:  Fanglin Guan; Chen Zhang; Shuguang Wei; Hongbo Zhang; Xiaomin Gong; Jiali Feng; Chengge Gao; Rong Su; Huanming Yang; Shengbin Li
Journal:  Hum Genet       Date:  2011-12-11       Impact factor: 4.132

5.  Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis.

Authors:  Larry J Seidman; Anthony J Giuliano; Eric C Meyer; Jean Addington; Kristin S Cadenhead; Tyrone D Cannon; Thomas H McGlashan; Diana O Perkins; Ming T Tsuang; Elaine F Walker; Scott W Woods; Carrie E Bearden; Bruce K Christensen; Keith Hawkins; Robert Heaton; Richard S E Keefe; Robert Heinssen; Barbara A Cornblatt
Journal:  Arch Gen Psychiatry       Date:  2010-06

Review 6.  Cellular reprogramming: recent advances in modeling neurological diseases.

Authors:  Guo-Li Ming; Oliver Brüstle; Alysson Muotri; Lorenz Studer; Marius Wernig; Kimberly M Christian
Journal:  J Neurosci       Date:  2011-11-09       Impact factor: 6.167

7.  Neuregulin directly decreases voltage-gated sodium current in hippocampal ErbB4-expressing interneurons.

Authors:  Megan J Janssen; Elias Leiva-Salcedo; Andres Buonanno
Journal:  J Neurosci       Date:  2012-10-03       Impact factor: 6.167

8.  Modulation of behavioral networks by selective interneuronal inactivation.

Authors:  M J Schmidt; S Horvath; P Ebert; J L Norris; E H Seeley; J Brown; L Gellert; M Everheart; K A Garbett; T W Grice; R M Caprioli; K Mirnics
Journal:  Mol Psychiatry       Date:  2013-12-10       Impact factor: 15.992

9.  MRI brain volume abnormalities in young, nonpsychotic relatives of schizophrenia probands are associated with subsequent prodromal symptoms.

Authors:  Beng-Choon Ho
Journal:  Schizophr Res       Date:  2007-08-29       Impact factor: 4.939

10.  Potential contribution of dopaminergic gene variants in ADHD core traits and co-morbidity: a study on eastern Indian probands.

Authors:  Subhamita Maitra; Kanyakumarika Sarkar; Paramita Ghosh; Arijit Karmakar; Animesh Bhattacharjee; Swagata Sinha; Kanchan Mukhopadhyay
Journal:  Cell Mol Neurobiol       Date:  2014-03-02       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.